SAB5300460
Monoclonal Anti-G6PD antibody produced in mouse
clone 2H7, ascites fluid
Synonym(s):
G6PD1
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
2H7, monoclonal
Application:
ELISA (d), FACS, IHC, WB
Citations:
1
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
2H7, monoclonal
mol wt
59 kDa
species reactivity
human
technique(s)
direct ELISA: 1:10,000, flow cytometry: 1:200-1:400, immunohistochemistry: 1:200-1:1,000, western blot: 1:500-1:2,000
isotype
IgG1
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... G6PD(2539)
Immunogen
Purified recombinant fragment of human G6PD expressed in E.coli.
Mouse monoclonal antibody raised against G6PD
Mouse monoclonal antibody raised against G6PD
Physical form
Ascitic fluid containing 0.03% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
Explore all of our products under Monoclonal Anti-G6PD antibody produced in mouse
— or —
Try our Product Selector Tool to narrow your options
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
wgk
nwg
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Naoki Mine et al.
Molecular cancer therapeutics, 13(9), 2215-2225 (2014-07-24)
CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patients with nonsquamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). CBP501 has been shown to have two mechanisms of action